AstraZeneca's Lynparza delays progression risk in prostate cancer
Pharmaceutical company AstraZeneca said on Tuesday that results from a recent study revealed that its Lynparza asset reduced the risk of first-line metastatic castration-resistant prostate cancer progression by 34% when used in combination with abiraterone.
AstraZeneca
11,780.00p
16:45 20/09/24
FTSE 100
8,229.99
17:14 20/09/24
FTSE 350
4,543.89
16:49 20/09/24
FTSE All-Share
4,501.08
17:04 20/09/24
Pharmaceuticals & Biotechnology
22,415.97
16:49 20/09/24
AstraZeneca stated the combination demonstrated "a statistically significant and clinically meaningful improvement" in radiographic progression-free survival versus current standard-of-care.
Susan Galbraith, AZN's executive vice president of Oncology R&D, said: "This Lynparza combination has the potential to afford first-line patients more time without disease progression while also maintaining their quality of life.
"The PROpel results are impressive because active comparator trials set a high bar and, in this trial, Lynparza plus abiraterone showed a significant clinical improvement when compared to an active standard of care in patients with metastatic castration-resistant prostate cancer, regardless of whether they have an HRR gene mutation."